+1 704-993-8389

Advocacy & Awareness for Immune Disorders Association (AAIDA)

Advocacy Initiatives

Congressional Letter Re Alternate Funding Program, April 17, 2023
Stakeholder Mental Health Letter on DEA Telemedicine Rule, March 28, 2023
CSL Behring Offers Copay Assistance Program For Privigen Starting January 3, 2023
AAIDA & IAF Advocate For Copay Assistance Program, October 11, 2022
Stakeholder Letter To Senate Urging Action On Telehealth Legislation This Fall, September 13, 2022
Role of PBM’s On Patient Access & Affordability of Prescription Drugs, May 24th, 2022
Comments on HHS Notice of Benefit and Payment Parameters for 2023 Proposed Rule, CMS-9911-P RIN 0938-AU65, January 27th, 2022
Support of BIOSIM Act, July 1st, 2021
Improving Patient Drug Affordability Through Standard Benefit Plan, July 28, 2021
Cigna’s $500 Incentive to Persuade Patients to Switch Therapies, April 16th, 2021
Low Cost Access to Generic Drugs, February 22nd, 2021
Proposed Medicaid Rebates Acceleration, February 2021
United Healthcare’s Mid-Year Change in Remicade Coverage a Concern for Stable Patients, January 25th, 2021 
Telehealth Access During the COVID-19 Public Health Emergency, November 10th, 2020
Policy Change Regarding Prior Authorizations and Site of Care Restrictions for IL-5/IL-5Ra agents, Nucala and Fasenra, May 2020